HepaRegeniX has begun dosing subjects in a Phase Ib trial of HRX-215 in subjects undergoing partial liver resection due to ...

Merck’s Enflonsia (clesrovimab) has received US Food and Drug Administration (FDA) approval for the prevention of respiratory ...

Arcutis Biotherapeutics has enrolled the first child in an open-label Phase II trial of Zoryve (roflumilast) for atopic ...

NewAmsterdam Pharma has reported encouraging topline data from a prespecified biomarker analysis of Alzheimer’s disease in a ...

Ascendis Pharma has reported week 26 interim analysis outcomes from the Phase II COACH Trial assessing TransCon CNP and ...

Daiichi Sankyo has announced the first subject dosing in the Phase III DESTINYEndometrial01 trial of Enhertu (trastuzumab ...

Sobi and Apellis Pharmaceuticals have reported new results from the open-label period of the randomised Phase III VALIANT ...

Industry experts gathered at the Outsourcing in Clinical Trials East Coast 2025 conference to discuss artificial intelligence ...

Regeneron and Sanofi have announced promising outcomes from the open-label Phase IV DISCOVER trial of Dupixent (dupilumab).

Avenzo Therapeutics has commenced the open-label Phase I/II trial of its CDK4 selective inhibitor, AVZO-023, for breast ...

Mediar Therapeutics has dosed the first subject in the Phase II WISPer trial of its investigational therapy, MTX-463, for IPF ...

Moleculin Biotech has announced encouraging topline efficacy outcomes from its US Phase IB/II trial, MB-107, of Annamycin.